Study population and design
infarct
INFARCT
This was a predefined substudy of the phase II, parallel arm, double-blind, randomised placebo-controlled, multicentre ASSAIL-MI trial (ClinicialTrials.gov, NCT03004703). The trial was performed at Oslo University Hospital Rikshospitalet, Oslo University Hospital Ullevål and St. Olavs Hospital, Trondheim, Norway.Eligible patients (between 18 and 80 years) were allocated in a 1:1 fashion to receive a single 1-hour intravenous infusion of 280 mg of tocilizumab or placebo. The infusion was started as soon as possible after obtaining oral consent from the patients, and the mean time from the start of the infusion to wire crossing was 8 min. The administration of tocilizumab/placebo did not delay the opening of the infarct related artery. This dose has been shown to achieve complete IL-6 receptor inhibition for 2–3 weeks.The primary endpoint of the ASSAIL-MI trial was MSI (